Single and dual quarter-dose blood pressure therapies showed significant efficacy (P<0.001) with significantly fewer adverse events than standard-dose monotherapy and similar safety to placebo.
Absolute Event Rate: 0% vs 0%
<0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.
Bennett et al. (Tue,) reported a other. Single and dual quarter-dose blood pressure therapies showed significant efficacy (P<0.001) with significantly fewer adverse events than standard-dose monotherapy and similar safety to placebo.